Recce Pharma doses first patients in Phase 3 Indonesian trials

Recce Pharmaceuticals (ASX:RCE) has taken a leap forward as it works towards creating the world’s first dedicated diabetic foot infection treatment, with patient dosing starting in its third-phase clinical trial in Indonesia this week.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

This content has been prepared as part of a partnership with Recce Pharmaceuticals Ltd and is intended for informational purposes only.

Recce CEO James Graham joined HotCopper to talk about the milestone trial in a Watchlist interview this week – watch the full video above.

Join the discussion. See what HotCopper users are saying about Recce Pharmaceuticals Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.